Literature DB >> 18043854

Skeletal differences in bone mineral area and content before and after cure of endogenous Cushing's syndrome.

L Füto1, J Toke, A Patócs, A Szappanos, I Varga, E Gláz, Z Tulassay, K Rácz, M Tóth.   

Abstract

UNLABELLED: We examined bone densitometric data in a four-year follow-up period before and after the cure of CS. Plasma cortisol concentrations were similar, but the duration of estimated glucocorticoid excess was longer in patients with prevalent bone fractures compared to those without fractures. After therapy of CS, bone area, BMC and BMD increased significantly at the LS and femur during follow-up, but they decreased at the forearm, suggesting redistribution of bone minerals from the peripheral to the axial skeleton.
INTRODUCTION: Only a few studies report the changes in bone mineral density (BMD) after the cure of Cushing's syndrome (CS).
METHODS: Forty-one patients with Cushing's disease, 21 patients with adrenal CS and 6 patients with ectopic CS were prospectively enrolled. BMD, bone mineral content (BMC) and bone area were measured by DXA.
RESULTS: No significant correlations were found between serum cortisol concentrations and baseline bone densitometric data. After successful therapy of CS, bone area and BMD increased significantly at the lumbar spine (LS) and femur during follow-up, but they decreased at the forearm. The progressive increase in BMC at the LS had a significant negative correlation with the change of the BMC of radius in the first and second follow-up years. The change in the body mass index was an independent predictor for changes in BMC both at the LS and at the forearm at the second year of remission.
CONCLUSIONS: The regional differences and the time-dependent changes of BMC suggest that the source of marked increase in axial BMC after the cure of CS is, at least partly, due to the redistribution of bone minerals from the peripheral to the axial skeleton.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18043854     DOI: 10.1007/s00198-007-0514-x

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  21 in total

1.  Increased risk of osteoporotic fractures in patients with Cushing's syndrome.

Authors:  Peter Vestergaard; Jørgen Lindholm; Jens Otto L Jørgensen; Claus Hagen; Hans Christian Hoeck; Peter Laurberg; Lars Rejnmark; Kim Brixen; Lars Ø Kristensen; Ulla Feldt-Rasmussen; Leif Mosekilde
Journal:  Eur J Endocrinol       Date:  2002-01       Impact factor: 6.664

2.  Bone mineral density at diagnosis and following successful treatment of pediatric Cushing's disease.

Authors:  S Scommegna; J P Greening; H L Storr; K M Davies; N J Shaw; J P Monson; A B Grossman; M O Savage
Journal:  J Endocrinol Invest       Date:  2005-03       Impact factor: 4.256

3.  Decreased bone area, bone mineral content, formative markers, and increased bone resorptive markers in endogenous Cushing's syndrome.

Authors:  K Godang; T Ueland; J Bollerslev
Journal:  Eur J Endocrinol       Date:  1999-08       Impact factor: 6.664

4.  Bone loss determined by quantitative ultrasonometry correlates inversely with disease activity in patients with endogenous glucocorticoid excess due to adrenal mass.

Authors:  L Tauchmanovà; R Rossi; V Nuzzo; A del Puente; A Esposito-del Puente; C Pizzi; F Fonderico; G Lupoli; G Lombardi
Journal:  Eur J Endocrinol       Date:  2001-09       Impact factor: 6.664

5.  Proximal femur bone mineral levels of US adults.

Authors:  A C Looker; H W Wahner; W L Dunn; M S Calvo; T B Harris; S P Heyse; C C Johnston; R L Lindsay
Journal:  Osteoporos Int       Date:  1995       Impact factor: 4.507

6.  Effect of 2 years of cortisol normalization on the impaired bone mass and turnover in adolescent and adult patients with Cushing's disease: a prospective study.

Authors:  Carolina Di Somma; Rosario Pivonello; Sandro Loche; Antongiulio Faggiano; Michele Klain; Marco Salvatore; Gaetano Lombardi; Annamaria Colao
Journal:  Clin Endocrinol (Oxf)       Date:  2003-03       Impact factor: 3.478

7.  Bone mineral density and bone turnover before and after surgical cure of Cushing's syndrome.

Authors:  A R Hermus; A G Smals; L M Swinkels; D A Huysmans; G F Pieters; C F Sweep; F H Corstens; P W Kloppenborg
Journal:  J Clin Endocrinol Metab       Date:  1995-10       Impact factor: 5.958

8.  Evaluation of bone mineral density of the peripheral skeleton in pre- and postmenopausal women with newly diagnosed endogenous Cushing's syndrome.

Authors:  N Karavitaki; G Ioannidis; F Giannakopoulos; P Mavrokefalos; N Thalassinos
Journal:  Clin Endocrinol (Oxf)       Date:  2004-02       Impact factor: 3.478

9.  Bone demineralization and vertebral fractures in endogenous cortisol excess: role of disease etiology and gonadal status.

Authors:  Libuse Tauchmanovà; Rosario Pivonello; Carolina Di Somma; Riccardo Rossi; Maria Cristina De Martino; Luigi Camera; Michele Klain; Marco Salvatore; Gaetano Lombardi; Annamaria Colao
Journal:  J Clin Endocrinol Metab       Date:  2006-03-07       Impact factor: 5.958

10.  Bone metabolism and mass in women with Cushing's syndrome and adrenal incidentaloma.

Authors:  Cristiano Maria Francucci; Paola Pantanetti; Gabriella Giuseppina Garrapa; Fernando Massi; Giorgio Arnaldi; Franco Mantero
Journal:  Clin Endocrinol (Oxf)       Date:  2002-11       Impact factor: 3.478

View more
  8 in total

1.  Treatment of skeletal impairment in patients with endogenous hypercortisolism: when and how?

Authors:  A Scillitani; G Mazziotti; C Di Somma; S Moretti; A Stigliano; R Pivonello; A Giustina; A Colao
Journal:  Osteoporos Int       Date:  2013-12-06       Impact factor: 4.507

2.  Glucocorticoid-induced osteoporosis: pathophysiological role of GH/IGF-I and PTH/VITAMIN D axes, treatment options and guidelines.

Authors:  Gherardo Mazziotti; Anna Maria Formenti; Robert A Adler; John P Bilezikian; Ashley Grossman; Emilia Sbardella; Salvatore Minisola; Andrea Giustina
Journal:  Endocrine       Date:  2016-10-20       Impact factor: 3.633

3.  Effects of Cushing disease on bone mineral density in a pediatric population.

Authors:  Maya B Lodish; Hui-Pin Hsiao; Anastasios Serbis; Ninet Sinaii; Anya Rothenbuhler; Margaret F Keil; Sosipatros A Boikos; James C Reynolds; Constantine A Stratakis
Journal:  J Pediatr       Date:  2010-03-10       Impact factor: 4.406

4.  Bone turnover in patients with endogenous Cushing's syndrome before and after successful treatment.

Authors:  A Szappanos; J Toke; D Lippai; A Patócs; P Igaz; N Szücs; L Füto; E Gláz; K Rácz; M Tóth
Journal:  Osteoporos Int       Date:  2009-06-10       Impact factor: 4.507

5.  Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline.

Authors:  Lynnette K Nieman; Beverly M K Biller; James W Findling; M Hassan Murad; John Newell-Price; Martin O Savage; Antoine Tabarin
Journal:  J Clin Endocrinol Metab       Date:  2015-07-29       Impact factor: 5.958

Review 6.  Quality of life and other outcomes in children treated for Cushing syndrome.

Authors:  Margaret F Keil
Journal:  J Clin Endocrinol Metab       Date:  2013-05-02       Impact factor: 5.958

7.  Assessment of non-traumatic vertebral fractures in Cushing's syndrome patients.

Authors:  T Apaydın; D G Yavuz
Journal:  J Endocrinol Invest       Date:  2021-01-09       Impact factor: 4.256

8.  Quantitative CT assessment of bone mineral density in dogs with hyperadrenocorticism.

Authors:  Donghoon Lee; Youngjae Lee; Wooshin Choi; Jinhwa Chang; Ji-Houn Kang; Ki-Jeong Na; Dong-Woo Chang
Journal:  J Vet Sci       Date:  2015       Impact factor: 1.672

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.